undamentalytics Newsletter
Sign in

Inovio Pharmaceuticals, Inc. income statement

In fiscal 2025, Inovio Pharmaceuticals, Inc. reported revenue of $65,343, down 70.0% on the year before, operating income of −$86.8m (a -132871.3% margin) and net income of −$84.9m, or −$1.81 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue96104131041354230472101000
Research and development9132018213458899995889424918887765448
General and administrative141212111416182428292737549048373331
Operating income−14−19−22−23−20−39−34−76−84−94−111−124−301−268−144−112−87−79
Interest expense————————008921100—
Income before tax————−66−36−31−74−88−95−121−163−303−278−135−107−85—
Income tax—00000−2002−0000000—
Net income−24−18−15−20−66−36−29−74−88−97−119−166−304−280−135−107−85−67
Diluted EPS−$0.33−$8.16−$5.76−$6.96−$17.16−$7.68−$5.28−$12.12−$13.08−$12.60−$14.52−$12.84−$17.45−$14.07−$6.09−$3.95−$1.81−$1.03
Diluted shares (average)—2m3m3m4m5m6m6m7m8m8m13m17m20m22m27m47m65m
EBITDA−14−19−21−23−19−39−33−75−82−90−108−121−298−264−141−111−85−78

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Inovio Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Inovio Pharmaceuticals, Inc.